Treatment Options for oHCM – Aligning Guidance With Real-World Data to Improve Outcomes

In this section, the experts will discuss the clinical transition from traditional nonspecific therapies, such as beta blockers and calcium channel blockers, to targeted options, such as mavacamten and aficamten, that address the underlying disease. This section highlights how real-world evidence (RWE) validates clinical trial data, specifically noting that 85% of patients in real-world settings achieved a reduction in obstruction (Valsalva LVOT gradient <30 mmHg) at a 32-month cutoff point. Furthermore, the discussion justifies the FDA-mandated monitoring protocols, explaining that the frequency of echocardiograms is rooted in robust RWE and the necessity of managing the risk of heart failure due to systolic dysfunction.